Stockscreener 앱 받기
1.06
1.92%
0.02
시간 외 거래:
1.07
0.01
+0.94%
Quince Therapeutics Inc 주식(QNCX)의 최신 뉴스
Quince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Down 42.9% in May - Defense World
FY2025 Earnings Forecast for TSE:WEE Issued By Roth Capital - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
HC Wainwright Has Positive Estimate for ORKA Q2 Earnings - Defense World
Q2 EPS Estimate for Century Therapeutics Raised by Analyst - Defense World
Rani Therapeutics (NASDAQ:RANI) Stock Price Up 7% – Here’s What Happened - Defense World
Finch Therapeutics Group (NASDAQ:FNCH) and Quince Therapeutics (NASDAQ:QNCX) Head to Head Comparison - Defense World
Brookline Capital Management Forecasts QNCX Q2 Earnings - Defense World
Quince Therapeutics secures USPTO nod for A-T treatment patent - MSN
Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026 (NASDAQ:QNCX) - Seeking Alpha
Quince Therapeutics Reports Q1 2025 Results and Strategic Updates - TipRanks
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results - BioSpace
Quince Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Quince Therapeutics, Inc. SEC 10-Q Report - TradingView
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results | QNCX Stock News - GuruFocus
Quince Therapeutics (QNCX) Expected to Announce Earnings on Monday - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Recommendation of “Buy” from Analysts - Defense World
Why Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Quince Therapeutics (QNCX) CEO to Present at Life Sciences Confe - GuruFocus
Quince Therapeutics (QNCX) CEO to Present at Life Sciences Conference - GuruFocus
Geode Capital Management LLC Has $703,000 Position in Quince Therapeutics, Inc. (NASDAQ:QNCX) - Defense World
Quince Therapeutics to Present at Citizens Life Sciences Conference - BioSpace
Quince Therapeutics Inc (QNCX) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Ratios Uncovered: Breaking Down Quince Therapeutics Inc (QNCX)’s Trailing Twelve Months Metrics - DWinneX
Closing Figures Unveiled: Quince Therapeutics Inc (QNCX) Drop -8.93, Closes at 1.02 - DWinneX
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Rating of “Buy” by Analysts - Defense World
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference - BioSpace
Rare Disease Biotech Quince to Unveil Latest Developments at Major Healthcare Conference - Stock Titan
Oppenheimer Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX) - MarketBeat
D. Boral Capital Issues Pessimistic Forecast for Quince Therapeutics (NASDAQ:QNCX) Stock Price - The AM Reporter
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
Quince Therapeutics (NASDAQ:QNCX) Price Target Lowered to $4.00 at D. Boral Capital - Defense World
Quince Therapeutics Reports 2024 Financial Results and Trial Progress - TipRanks
Quince Therapeutics stock target cut to $4 from $12, maintains buy By Investing.com - Investing.com South Africa
Quince Therapeutics stock target cut to $4 from $12, maintains buy - Investing.com
Quince Therapeutics (NASDAQ:QNCX) Now Covered by Oppenheimer - Defense World
Quince Therapeutics Existing Cash Position To Provide Operating Runway Through Phase 3 Topline Results Into 2026 - MarketScreener
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results - Business Wire
Oppenheimer sets $10 target for Quince Therapeutics stock By Investing.com - Investing.com South Africa
Oppenheimer Initiates Coverage of Quince Therapeutics (QNCX) with Outperform Recommendation - Nasdaq
Oppenheimer Initiates Quince Therapeutics at Outperform -March 24, 2025 at 07:46 am EDT - Marketscreener.com
Oppenheimer sets $10 target for Quince Therapeutics stock - Investing.com
Quince Therapeutics Files For Common Stock Offering Of Up To $21.9 MillionSEC Filing - marketscreener.com
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Recommendation of “Buy” by Analysts - The AM Reporter
Quince Therapeutics (QNCX) Projected to Post Earnings on Monday - Defense World
Analysts Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Target Price at $9.50 - Defense World
Quince Therapeutics (NASDAQ:QNCX) versus IN8bio (NASDAQ:INAB) Critical Contrast - Defense World
Market Momentum Report: Quince Therapeutics Inc (QNCX)’s Negative Close at 1.41 - The Dwinnex
Pliant, Acelyrin resort to ‘poison pills’ as threat of Concentra buyout looms - Fierce Biotech
Vaxart (NASDAQ:VXRT) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Comparison - Armenian Reporter
Ataxia Treatment Market Size in the 7MM is expected to grow - openPR
Financial Survey: Quince Therapeutics (NASDAQ:QNCX) & Vaxart (NASDAQ:VXRT) - Defense World
6.48%
자본화:
|
볼륨(24시간):